XSHE300204
Market cap463mUSD
Jan 09, Last price
7.11CNY
1D
-0.42%
1Q
-4.18%
Jan 2017
-59.90%
IPO
4.62%
Name
Staidson (Beijing) Biopharmaceuticals
Chart & Performance
P/E
—
P/S
9.33
EPS
—
Div Yield, %
0.03%
Shrs. gr., 5y
-0.16%
Rev. gr., 5y
-14.69%
Revenues
364m
-33.66%
Net income
-399m
CFO
-227m
Dividend
May 17, 20190.66807 CNY/sh
Earnings
Apr 16, 2025
Profile
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases. The company has a strategic collaboration with Pivotal S.L. to assess BDB-001, a monoclonal anti-C5a antibody, in a clinical trial in Europe in progressive severe COVID-19 patients caused by SARS-CoV-2. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 364,175 -33.66% | 548,989 -6.04% | |||||||
Cost of revenue | 628,874 | 740,340 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (264,699) | (191,351) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 32,445 | ||||||||
Tax Rate | |||||||||
NOPAT | (297,144) | (191,351) | |||||||
Net income | (398,893) | ||||||||
Dividends | (1,024) | ||||||||
Dividend yield | 0.02% | ||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 40,952 | 2,689 | |||||||
Long-term debt | 6,358 | ||||||||
Deferred revenue | 33,472 | ||||||||
Other long-term liabilities | 29,238 | 1 | |||||||
Net debt | (593,763) | (778,413) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (227,474) | ||||||||
CAPEX | (32,151) | ||||||||
Cash from investing activities | 16,992 | 321,323 | |||||||
Cash from financing activities | 30,636 | 32,618 | |||||||
FCF | (232,937) | (173,576) | |||||||
| Balance | |||||||||
Cash | 85,181 | 264,988 | |||||||
Long term investments | 549,535 | 522,472 | |||||||
Excess cash | 616,507 | 760,010 | |||||||
Stockholders' equity | 566,157 | 913,770 | |||||||
Invested Capital | 524,701 | 626,071 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 474,872 | 475,358 | |||||||
Price | 10.16 -25.29% | 13.60 -22.51% | |||||||
Market cap | 4,824,703 -25.37% | 6,464,863 -22.25% | |||||||
EV | 4,230,940 | 5,686,450 | |||||||
EBITDA | (232,249) | (157,360) | |||||||
EV/EBITDA | |||||||||
Interest | 1,345 | 358 | |||||||
Interest/NOPBT | |||||||||